Global roadmap sets 2030 targets for children’s medicines
The GAP-f partnership will focus on high-burden diseases, priority products and stronger access systems in ten countries.

A global health partnership has set new targets to improve the development and availability of medicines designed for children by 2030.
The Global Accelerator for Paediatric Formulations, known as GAP-f, will assess product needs across ten high-burden diseases, accelerate ten priority medicines and strengthen paediatric medicine systems in ten countries.
Children often need formulations that differ from adult medicines in dose, strength and delivery. The roadmap aims to connect research, product development, regulation and country-level access so suitable treatments reach young patients sooner.
The partnership will also maintain a portfolio of priority products and provide resources for clinical research involving children. Its country work is intended to help health systems identify gaps and introduce appropriate formulations.
The 2025–2030 roadmap brings governments, researchers, funders and manufacturers around a shared set of milestones, with progress measured against the programme’s 30 by ’30 commitment.
Source
News brief based on the linked World Health Organization announcement.